FDA approves Liposorber Apheresis System for pediatric use

Author(s):

On Oct. 10, the U.S. Food and Drug Administration (FDA) approved Liposorber LA-15 System to treat pediatric patients with primary focal segmental glomerulosclerosis (FSGS) either before transplant, or after renal transplantation when there is recurrence of FSGS. Read more.

LEAVE A REPLY

Please enter your comment!
Please enter your name here